COVID-19

COVID-19

COVID-19 Vaccine Immunogenicity Evaluation: Breakthrough Enzyme-Linked Immunosorbent Assay for Emerging Variants

Researchers from Novavax Inc. have published a groundbreaking study on COVID-19 vaccine immunogenicity evaluation, introducing a novel enzyme-linked immunosorbent assay (ELISA) to assess antibody responses against emerging SARS-CoV-2 variants. The study highlights the importance of clinical immunogenicity biomarkers in addressing the growing threat of immune evasion posed by emerging variants.